Navigation Links
SemBioSys announces first quarter 2008 financial and operational results
Date:5/9/2008

ements reflect the Company's current expectation and assumptions, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated. These forward-looking statements involve risks and uncertainties including, but not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time-to-time in the Company's ongoing filings with the Canadian securities regulatory authorities which filings can be found at http://www.sedar.com. Given these risks and uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements. The Company undertakes no obligation to publicly update or revise any forward-looking statements either as a result of new information, future events or otherwise, except as required by applicable Canadian securities laws.

SemBioSys Genetics Inc.

Consolidated Balance Sheets

(Unaudited)

-------------------------------------------------------------------------

(expressed in Canadian dollars)

March 31, December 31,

2008 2007

$ $

-------------------------------------------------------------------------

Assets

Current assets

Cash and cash equivalents 16,284,778 20,444,013

Accounts receivable 150,468 583,591

Interest receivable 100,572 30,321

Prepaid expenses and deposits 452,613 538,718

Inv
'/>"/>

SOURCE SemBioSys Genetics Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. SemBioSys receives milestone payments from AVAC Ltd.
2. SemBioSys initiates toxicology study for safflower-produced insulin
3. SemBioSys announces 2007 financial and operational results
4. SemBioSys GLA Partner Enters Strategic Alliance for the Sales and Marketing of GLA-Rich Safflower Oil
5. SemBioSys awarded key patent for the production of oleosome emulsions by the European Patent Office
6. SemBioSys to present at the 10th Annual BIO CEO & Investor Conference
7. SemBioSys signs option agreement for safflower-produced food ingredient
8. SemBioSys announces 2007 third quarter results
9. SemBioSys to present insulin data at the Seventh Annual Diabetes Technology Meeting
10. SemBioSys updates Apo AI development program
11. Takeda Successfully Completes Tender Offer for Millennium Pharmaceuticals, Inc. and Announces Subsequent Offering Period
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... LONDON , December 23, 2014 ... Review Algeria , out today and available for free ... the actors driving change and growth in the sector today. ... has scored notable successes has been in developing a homegrown ... 70 percent local production still remains some way off. A ...
(Date:12/22/2014)... Md. , Dec. 22, 2014 /PRNewswire/ ... SYN), a developer of pathogen-specific therapies for ... on protecting the microbiome, today announced positive ... Phase 1a clinical trial of SYN-004, the ... prevention of Clostridium difficile (C. difficile) ...
(Date:12/22/2014)... The American Journal of ... research, reviews and editorials addressing developments and pathways ... published a provocative article exploring the role of ... potential treatment of prostate cancer. , The ... the possibility that there could be a connection ...
(Date:12/19/2014)... 19, 2014 BioPlus Specialty Pharmacy ... announces the promotion of Nick Maroulis, Pharm.D. to the ... Services. , In this position, Dr. Maroulis will ... managing the directors of our multi-site pharmacies as the ... 1997 and during that time he has served in ...
Breaking Biology Technology:PharmaBoardroom Releases New Algeria Pharmaceuticals Report 2PharmaBoardroom Releases New Algeria Pharmaceuticals Report 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 2Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 4Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 5Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 2Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 3Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 4BioPlus Specialty Pharmacy Promotes Dr. Nick Maroulis to Vice President of Specialty Pharmacy Services 2
... SAN DIEGO, March 4, 2011 Volcano Corporation (Nasdaq: ... of precision guided therapy tools designed to enhance the ... announced today that it received clearance to market the ... will introduce the device at the 20th PCI Live ...
... SACRAMENTO, Calif., March 3, 2011 Claims that Assembly ... preserve a physical therapist,s license made by the author ... than a smokescreen contends the California Physical Therapy Association ... world. AB 783 amends sections of the ...
... (ASX: HZL; OTCQX: HLTZY) announced that it has entered ... ("the Trout Group"), a leading New York-based investor relations ... investor relations services for Healthzone for an initial engagement ... current clients, the Trout Group provides investor relations and ...
Cached Biology Technology:Volcano Announces the Introduction of the Eagle Eye® Platinum Digital IVUS Catheter at the 20th PCI Live Demonstration Course in Kurashiki 2Volcano Announces the Introduction of the Eagle Eye® Platinum Digital IVUS Catheter at the 20th PCI Live Demonstration Course in Kurashiki 3False Claims by Supporters Swirl Around Hayashi Bill 2Healthzone Limited Engages The Trout Group for Investor Relations Services 2
(Date:12/17/2014)... , Dec. 15, 2014  HITLAB SM ... Clinical Practices (GCP) audit to confirm its adherence ... regulations. This accomplishment enables HITLAB to conduct regulated ... the highest principles for patient safety and research ... global healthcare access, quality, and delivery with innovative ...
(Date:12/17/2014)... --Research and Markets ( http://www.researchandmarkets.com/research/9zq33j/global_chemical ) ... Chemical Sensor Market 2015-2019" report to their ... One major trend upcoming in this ... in biomedical applications. Chemical sensors help in recording ... during surgical procedures. The Global Chemical Sensor market ...
(Date:12/15/2014)... 12, 2014 Research and Markets ... the "Global Facial Recognition Market 2015-2019" ... http://photos.prnewswire.com/prnh/20130307/600769 Facial recognition is ... Facial recognition system measures the overall facial feature ... mouth, and the distance between eyes. Facial recognition ...
Breaking Biology News(10 mins):HITLAB Completes GCP Audit for FDA Smart Device & App Compliance 2Global Chemical Sensor Market 2015-2019: Key Vendors are Abbott Laboratories, Bayer, Hoffmann La-Roche, Johnson & Johnson, NGK Spark Plugs and Robert Bosch 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 3
... Beverly Hills, Calif. and Washington DC (ASRM Annual Meeting) ... patients undergoing in-vitro fertilization (IVF) is improved when doctors ... embryos to the point where the endometrium is most ... the 63rd Annual Meeting of the American Society for ...
... Delaware has been named a regional research participant in ... health ever conducted in the United States. The ... Health, will follow an estimated 100,000 children in communities ... years of age. It will seek information to prevent ...
... help us think, in addition to its well-known role ... cells. We hypothesize that blood actively ... principle investigator in the McGovern Institute for Brain Research ... of Neurophysiology. Many lines of evidence suggest that blood ...
Cached Biology News:In-vitro fertilization improved with 3-D/4-D-guided embryo transfer and new placement target 2In-vitro fertilization improved with 3-D/4-D-guided embryo transfer and new placement target 3UD named a regional research participant in National Children’s Study 2MIT: blood may help us think 2
Human VEGF R Phycoerythrin Sampler (Cl 89106, 49560, 54733)...
... Beagle Serum • Beagle serum is ... over one year of age Available Anticoagulants: ... Heparin (Na) N-06: K2EDTA N-08: ... N-03: Alsevers N-05: ACD ...
... Kit is designed to purify double-stranded DNA (dsDNA) ... and PCR. The process is simple and fast. ... g can be efficiently purified and concentrated. The ... is bound to the Microfilter Cartridge in the ...
This BioSolution package is excellent for doing fluorescence thermal melt experiments on nucleic acids, studies involving biomolecular interactions, protein folding experiments, and more!...
Biology Products: